Leiomyosarcoma Patient Discusses Treatment Roadmap, Challenges

Beth Wallace discusses various treatments for leiomyosarcoma, including doxorubicin (Adriamycin), nicknamed the red devil.

Beth Wallace discusses various treatments for leiomyosarcoma, including doxorubicin (Adriamycin), nicknamed the red devil.

Related Videos
Related Content

Clinical Trial Shows Benefit of Veliparib in ‘BRCA-Like’ Breast Cancer

February 6th 2023

Pharmacy Focus: Psychedelic Pharmacy - Understanding Natural vs. Synthetic Psychedelics

January 13th 2023

FDA Grants Orphan Drug Designation to Belimumab for Systemic Sclerosis Treatment

February 6th 2023

Pharmacy Focus: Public Health Matters- Celebrating American Pharmacist Month Part 2 with Autumn Zuckerman

October 13th 2022

FDA Approves Sacituzumab Govitecan-hziy for HR+/HER2- Metastatic Breast Cancer

February 3rd 2023

Biosimilars Found to Produce Cost Savings Despite Increased Consumption Volume

February 3rd 2023

Clinical Trial Shows Benefit of Veliparib in ‘BRCA-Like’ Breast Cancer

February 6th 2023

Pharmacy Focus: Psychedelic Pharmacy - Understanding Natural vs. Synthetic Psychedelics

January 13th 2023

FDA Grants Orphan Drug Designation to Belimumab for Systemic Sclerosis Treatment

February 6th 2023

Pharmacy Focus: Public Health Matters- Celebrating American Pharmacist Month Part 2 with Autumn Zuckerman

October 13th 2022

FDA Approves Sacituzumab Govitecan-hziy for HR+/HER2- Metastatic Breast Cancer

February 3rd 2023

Biosimilars Found to Produce Cost Savings Despite Increased Consumption Volume

February 3rd 2023

Clinical Trial Shows Benefit of Veliparib in ‘BRCA-Like’ Breast Cancer

February 6th 2023

Pharmacy Focus: Psychedelic Pharmacy - Understanding Natural vs. Synthetic Psychedelics

January 13th 2023

FDA Grants Orphan Drug Designation to Belimumab for Systemic Sclerosis Treatment

February 6th 2023

Pharmacy Focus: Public Health Matters- Celebrating American Pharmacist Month Part 2 with Autumn Zuckerman

October 13th 2022

FDA Approves Sacituzumab Govitecan-hziy for HR+/HER2- Metastatic Breast Cancer

February 3rd 2023

Biosimilars Found to Produce Cost Savings Despite Increased Consumption Volume

February 3rd 2023
About Us
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.